(Q61853687)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

title

Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Wen-Fang Cheng

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Angiolo Gadducci

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

4

Anil K Sood

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

author name string

Christoph Grimm

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Alexander Reinthaller

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Lukas A Hefler

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

Clemens B Tempfer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

language of work or name

English

0 references

publication date

5 June 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

volume

103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

page(s)

512-517

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

29 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Angiogenesis in cancer, vascular, rheumatoid and other disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Vascular endothelial growth factor serum concentrations in ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Raloxifene therapy in postmenopausal women is associated with a significant reduction in the concentration of serum vascular endothelial growth factor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Changes in serum levels of vascular endothelial growth factor in males and females throughout life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: association with changes in ovarian and uterine Doppler blood flow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2006.03.058

10.1016/J.YGYNO.2006.03.058

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16750560%20AND%20SRC:MED&resulttype=core&format=json

29 January 2020

1 reference